Objective. To investigate the mechanism explaining the persistence of human immunodeficiency virus (HIV) type 1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy.
The development of HIV-1 protease inhibitor (PI) resistance is a stepwise process [1] [2] [3] . The first mutations selected (primary mutations) are usually located at or near the substrate-binding cleft of the enzyme. They cause a reduced affinity of the viral protease for the PI, thereby resulting in PI resistance. Subsequently, secondary mutations appear in the viral protease, leading to a further increase in the level of resistance [4] . Re-sistance mutations lead not only to reduced affinity for the PI but also to a reduced affinity for the natural substrate of the viral protease-namely, the Gag and GagPol polyprotein precursors-resulting in a reduction in viral replication capacity (RC) [5] [6] [7] . Replication during continuous PI pressure can lead to a compensation for the initial decrease in RC by the selection of compensatory mutations within protease [7] [8] [9] [10] . In addition, changes in the protease cleavage sites-most notably the NC/p1 and p1/p6 cleavage sites-and at other positions in Gag have been described. In individual cases it has been shown that full compensation of a reduced RC toward wild-type levels is possible through the acquisition of multiple compensatory mutations [9] [10] [11] . However, in most cases PI-resistant viruses from patients experiencing PI therapy failure have not fully compensated for the initial loss in RC [12] .
In the last few years, several studies have shown that transmission of drug-resistant HIV-1 is quite common in developed countries [13] [14] [15] . Cumulative data in-dicate that PI-resistant viruses can persist in vivo after transmission for a prolonged period of time in the absence of drug pressure [16] [17] [18] . This is despite the fact that most PI-resistant viruses have a reduced RC, compared with that of wild-type virus. Recently, it was also shown that PI-resistant viruses persisted during a median 42 weeks of follow-up in patients who discontinued their PIs while continuing their reverse-transcriptase inhibitors (RTIs) [19] . Also in highly PI-experienced patients who were switched from a PI-containing regimen to a new regimen without PIs, the persistence of PI-resistant viruses was observed [20] .
On the other hand, (partial) reversion of PI-resistant viruses in the direction of wild type in the absence of PI pressure has also been observed, both after transmission as well as after stopping PIs while continuing RTIs [19, 21, 22 ]. The question is, then: which factors determine why some PI-resistant viruses persist in absence of PI pressure while other PI-resistant viruses revert back to wild type? Therefore, we closely investigated the in vivo persistence of PI-resistant viruses in 2 HIV-1-infected patients who stopped their PI therapy for 4 years while their RTI therapy was continued.
MATERIALS AND METHODS
Patients. For this study, 2 patients (A and B) were selected from our outpatient clinic. At baseline, the HIV-1 RNA load of patient A was unavailable, and his CD4 cell count was 160 cells/mm 3 ( figure 1A ). Therapy was initiated in 1996 and in 1998 was changed to zidovudine, lamivudine, nevirapine, and nelfinavir ( figure 1A) . Because of toxicity, the PI nelfinavir was stopped in 2001, and the RTIs zidovudine, lamivudine, and nevirapine were continued. After stopping the PI, during a follow-up period of 4 years, HIV-1 RNA load (∼1000 copies/ mL) and CD4 cell count (∼400 cells/mm 3 ) remained stable. The baseline HIV-1 RNA load of patient B was unavailable, and his baseline CD4 cell count was 1446 cells/mm 3 (figure 1B). Between 1991 and 1996, patient B received several sequential antiretroviral regimens, and, in 1996, a highly active antiretroviral therapy regimen with lamivudine, stavudine, and indinavir was initiated. Because of toxicity, the PI indinavir was stopped in 2001, and the nucleoside RTIs (NRTIs) lamivudine and stavudine were continued. After stopping the PI, during a follow-up period of 4 years, HIV-1 RNA load (∼1000 copies/ mL) and CD4 cell count (∼800 cells/mm 3 ) remained stable. From both patients, several plasma/serum samples, as depicted in figure 1 , were analyzed. Viral RNA analysis. Viral RNA was isolated from 200 mL of plasma/serum according to the method described by Boom et al. [23] . Subsequently, the isolated viral RNA was used to reverse transcribe and amplify viral protease and the C-terminus of Gag (including the p2/NC, NC/p1, and p1/p6 cleavage sites), essentially as described previously [24, 25] . Subsequently, the polymerase chain reaction (PCR) product was used for sequence analysis with the BigDye Terminator Cycle Sequencing Kit (version 1.1; Applied Biosystems) [26] . Furthermore, the isolated viral RNA was used to reverse transcribe, amplify, and sequence the N-terminus of RT, as described elsewhere [24, 27] .
Viral replication experiments. The amplified products of the viral protease and C-terminus of Gag, including the p2/ NC, NC/p1, and p1/p6 cleavage sites, were subsequently used to create recombinant viruses representing the virus population, as described elsewhere [25] . For each recombinant virus batch, the amount of p24 was determined by ELISA (AMPAK; DAKO) [28] . Viral replication experiments were performed by infecting SupT1 cells with 100 ng of p24 of each recombinant 6 2.0 ϫ 10 virus batch. After 2 h of incubation, the cells were washed twice with RPMI 1640 medium with l-glutamine (Cambrex) and were resuspended in 10 mL of RPMI 1640 medium with lglutamine supplemented with 10% fetal calf serum (FCS; Gibco) and gentamycin (10 mg/mL; Invitrogen). Cultures were maintained for 12 days, and twice each day 150 mL of cell-free viral supernatant was taken for p24 analysis. Generation of site-directed mutants. To investigate whether persistence of drug-resistant protease mutants can be explained by a reduced RC of intermediate variants, a recombinant virus clone (B6) representing the virus population of patient B after stopping PI was selected. In this recombinant virus clone, primary and secondary mutations in protease were reverted to wild type by site-directed mutagenesis. In each clone, one of the following primary or secondary mutations was reverted to wild type: 46I, 54V, 82A, or 90M. Therefore, PCR was performed on plasmid DNA with Vent R DNA polymerase (New England BioLabs) with the primers 5 -p2 and 3 -prot2 as well as a third primer, which was either PR-I46M (5 -ATG GAA ACC AAA AAT GAT AGG GGG AAT-3 ; nt 2375-2401), PR-V54I (5 -ATA GGG GGA ATT GGA GGT TTT ATC AGA GTA-3 ; nt 2391-2420), PR-A82V (5 -AGG ACC TAC ACC TGT CAA CAT AAT TGG AAG-3 ; nt 2483-2512), or PR-M90L (5 -TTG GAA GAA ATC TGT TGA CTC AGC TTG GT-3 ; nt 2506-2534). Subsequently, recombinant viruses were created, and viral replication experiments were performed.
In vitro evolution experiments. To investigate the potential evolutionary pathways, 6 individual in vitro evolution experiments were performed for each recombinant virus, as described elsewhere [26] . Briefly, a recombinant virus clone (B6) representing the population of patient B after stopping PI or its corresponding site-directed mutants with 1 primary/secondary mutation reverted to wild type were used to infect SupT1 cells ( ). Twice a week, half of the cultures were replenished 6 0.2 ϫ 10 with fresh RPMI 1640 medium with l-glutamine supplemented with 10% FCS (Gibco) and gentamycin (10 mg/mL; Invitrogen). 
Viral replication was monitored by cytopathic effect (CPE).
When full-blown CPE was observed, virus was harvested, and ∼30-100 mL of culture supernatant was used to perform a new passage. After 10 passages, the viral protease and the C-terminus of Gag were amplified from viral RNA and sequenced.
To ensure that there were a sufficient number of replication cycles, in vitro evolution experiments were performed using a protease mutant (36I, 54V, or 82T) with a severely reduced RC. As in previous in vitro evolution experiments, an increase in RC through several evolutionary pathways, either by loss of A recombinant virus clone representing the viral population in patient B 3 years after PI therapy was stopped was created. In this recombinant virus clone, primary/secondary mutations in protease (46M, 54V, 82A, and 90M) were reverted to wild type by site-directed mutagenesis. With these site-directed mutants, viral replication experiments were performed in SupT1 cells. Viral replication was monitored by p24 production in the culture supernatant. Shown is the mean of duplicate experiments.
mutations or by the acquisition of a compensatory change (A71V), was observed (data not shown) [26] .
RESULTS

Long-Term Persistence of Protease Mutants during Partial Treatment Interruption (PTI)
Patient A. During the sequential PI-containing regimens, the viral population accumulated substitutions in protease and Gag ( figure 2A and 2B ). Sample A3, taken just before the PI nelfinavir was stopped, harbored the following changes in protease: I10V, V32I, L33F, M46I, A71V, V82A, and L90M, of which the M46I, V82A, and L90M changes are generally considered to be primary resistance mutations [29] . The virus also harbored a PI-associated change in the NC/p1 cleavage site (A431V) and a duplication of the PTAP motif in p6 gag present as a 14-aa insertion in mixture, as was revealed by clonal sequencing. During 4 years of follow-up in the absence of PI pressure, all protease and Gag mutations persisted.
The persistence of mutations in protease and Gag was apparently not caused by the absence of viral replication and evolution. After stopping the PI, continuous evolution of the viral protease gene occurred as shown by the appearance of mixtures (R41R/K, H69Q/K, I72I/M, and I93I/M) and a homogenous change (K55R) in protease.
Analysis of the RT gene just before the PI was stopped revealed the presence of 3 mutations (K70K/R, M184V, and K103N) causing resistance to zidovudine, lamivudine, and nevirapine, respectively. During continuous treatment with zidovudine, lamivudine, and nevirapine, a change from the K70K/R mixture to a homogenous mutant population (K70R) and selection of a mixture at position 219 (K219K/Q) was observed, whereas all other RT mutations persisted.
Patient B. During several PI-containing regimens, the viral population of patient B also developed several mutations in protease, including M36I, M46I, I54V, A71T, V82A, and L90M, of which M46I, V82A, and L90M are generally considered to be primary resistance mutations. In addition, a change in Gag (NC/p1 cleavage site A431V) was observed ( figure 2C and 2D) . After stopping the PI for 14 years, all protease mutations persisted either as homogenous substitutions or as mixtures (M36I/M and V82A/V). Furthermore, the A431V substitution in the NC/p1 cleavage site persisted, and a mixture in the p2/ NC cleavage site (T375N/S) evolved toward a T375S change. Also in this patient, continuous viral replication and evolution of the viral population after stopping the PI was observed, as shown by the appearance of 4 mutations in protease, which either remained present as mixtures (I13I/V, K14K/R, and L33L/ I) or as a homogenous change (N37D).
Analysis of RT just before stopping the PI demonstrated the presence of several thymidine analogue mutations (M41L, D67N, K70R, T215F, and K219E) as well as a lamivudineselected change, M184V. During continuous treatment with zidovudine and stavudine, all substitutions in RT persisted with the exception of D67N, which changed into D67G.
Persistence of Protease Mutants despite a Reduced RC
Recombinant viruses representing the viral population of patient B before and during PI treatment and after stopping the PI were created. Subsequently, the RC of these recombinant viruses was determined by performing viral replication experiments in SupT1 cells. As shown in figure 3A , the wild-type virus population of patient B (B1) replicated comparably to our reference strain HXB2. In contrast, the population obtained during PI therapy (B3) harboring 3 primary resistance mutations in protease (M46I, V82A, and L90M) had a reduced RC compared with the wild-type population (B1). Remarkably, the population obtained 3 years after stopping the PI (B6) still had a reduced RC, which was comparable to that of the virus obtained just before the PI was stopped (B3).
Persistence of Protease Mutants In Vitro
Both patients had low HIV-1 RNA loads (1000 copies/mL) during the period after PI therapy was stopped. Part of the explanation for the persistence of PI mutations in the absence of therapy could be that the in vivo levels of replication were very low and as a consequence no (back)-mutations could be generated and selected. To investigate this, a recombinant virus clone (B6) containing the protease gene of the virus from patient B 3 years after PI was stopped was created and used to perform in vitro evolution experiments in which high-level replication was allowed. In 6 individually performed experiments, all protease mutations, including the primary resistance mutations, persisted (table 1) . Moreover, mixture populations at the NC/p1 cleavage site (G435G/E) and at amino acid G412G/S in Gag appeared. These data suggest that the in vivo persistence of PI-resistant viruses in this patient cannot be attributed to limited viral replication.
Reversion to Wild Type Is Prohibited by a Reduced RC of Intermediate Variants
Taking into account that the effective viral population size is relatively small [30] [31] [32] [33] , we hypothesized that reversion to wild type of PI-resistant variants with multiple mutations in protease is most likely to occur through sequential single changes. However, any intermediate virus with a single change that is generated can only gain dominance if its RC is higher than its predecessor. If changing an individual amino acid leads to a further reduction in RC, reversion to wild type will be blocked, resulting in persistence of a virus with multiple mutations and a reduced RC, a situation that can be referred to as "compensatory fixation."
To investigate our hypothesis that reversion to wild type is prohibited by a reduction in the RC of intermediate variants, the recombinant virus clone (B6) representing the virus population after PI therapy was stopped was used for site-directed mutagenesis. Single positions (46I, 54V, 82A, or 90M) were reverted to wild type, and RC was measured. Indeed, changing the 54 valine or the 82 alanine mutations to wild type led to a further decrease in RC (figure 3B). The most severe reduction in RC was observed when the 46 isoleucine mutation was changed to wild type. Reversion of the 90 methionine mutation to wild type did not have a large effect on RC; however, with the assay used here we cannot exclude small differences in RC.
In vitro evolution experiments in the absence of drugs were performed using all these site-directed mutants (Ϫ46I, Ϫ54V, Ϫ82A, or Ϫ90M) to investigate whether subsequent secondary single-step reversions could lead to an increase in RC. None of these viruses lost additional protease-resistance mutations when cultured in the absence of drug. In most experiments, the appearance of new changes in protease and/or Gag was observed (table 1 ). These data demonstrate that even when In vitro evolution experiments with a recombinant virus clone (B6) representing the viral population in patient B 3 years after protease inhibitor therapy was stopped and with its corresponding site-directed mutants (Ϫ46I, Ϫ54V, Ϫ82A, or Ϫ90M). Protease   10  13  16  17  21  35  36  37  45  46  54  55  57  62  63  71  82  90  93  95 Consensus
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already 1 mutation in protease was reverted to wild type, the viruses still were not able to evolve in the direction of wildtype virus. This strongly supports our hypothesis that reversion to wild type is prohibited due to the reduced RC of intermediate variants.
DISCUSSION
In this study, a mechanism explaining in vivo persistence of viruses with multiple PI mutations is proposed. We studied the evolution of HIV-1 protease in 2 HIV-1-infected patients who stopped their PI therapy for reasons of toxicity while RTIs were continued. We demonstrate persistence of protease mutations during a prolonged follow-up period of almost 4 years (in the absence of PIs). Moreover, large-scale in vitro evolution experiments using a recombinant virus harboring patient-derived protease also demonstrated the persistence of these protease mutations. This is remarkable, given that the PI-resistant virus population had a decreased RC, compared with that of wild type. The common belief is that PI-resistant viruses, with a re-Gag (aa 373-500)   375  378  380  389  401  403  411  412  425  427  431  435  443  449  468  469  473  482 483
duced RC, disappear from plasma once PI pressure is removed. There are 2 potential pathways for the disappearance of these RC-impaired variants. The most straightforward option is that archived wild-type virus reappears and outgrows the PI-resistant population with a reduced RC. However, in the 2 patients we studied, this was not a likely option considering that the archived wild-type virus also has a wild-type RT (assuming that the chances of recombination were very low). Because our patients continued the use of RTIs, the reappearance of wild-type virus was blocked. The alternative pathway to wild-type protease would be through gradual reversion of mutations. Here, we demonstrate 2 lines of evidence indicating that the evolution back to wild-type virus is blocked. First, we show that changing a single primary/secondary resistance mutation in protease (M46I, I54V, V82A, or L90M) to wild type results in an even further reduction in RC, driving the virus into a fitness valley. Second, continuous in vitro passaging of these site-directed mutants demonstrated that even these variants could not evolve toward wild type. Together, these data demonstrate that persistence of viruses with multiple PI-resistance mutations and a reduced RC can be explained by the observation that the route to wild-type virus is blocked-a situation we would refer to as compensatory fixation.
In our in vitro analysis, we used the patient-derived viral protease and C-terminal part of Gag in the background of a reference virus (HXB2). It cannot be ignored that variation in other parts of the viral genome may also influence viral RC and evolution. One can also hypothesize that alternative mechanisms may play a role in the long-term persistence of multiple PI-resistance mutations in the plasma of the patient. First of all, the observed persistence could be the result of the low viral load during PTI (∼1000 copies/mL). However, the viral population in both patients after stopping PI therapy demonstrated the generation and selection of mutations, indicating that there was continuous replication and evolution. In addition, in vitro evolution experiments using a recombinant virus clone resembling the viral population during PTI and allowing high-level replication also demonstrated the persistence of protease mutations and the selection of additional amino acid changes in the viral protease or Gag region. Furthermore, it has been shown in a study by Deeks et al. [19] that persistence of protease mutations during PTI of the PI therapy is not restricted to patients with a low viral load. It was demonstrated that patients with a load of ∼4 log 10 copies/mL also showed persistence of protease mutations during PTI.
Second, we cannot exclude the possibility that immune pressure may play an additional role, especially since most protease mutations are located in cytotoxic T lymphocyte epitopes [34] . However, if immune pressure indeed plays a major role in vivo, no consistency should have been observed between the in vivo and in vitro persistence of PI-resistance mutations.
The data from this study may explain why some PI-resistant viruses persist in vivo after transmission to a new host [16] [17] [18] whereas others gradually revert to wild type [21, 22] . It is generally assumed that the viral inoculum is small and, therefore, that the chances that a patient becomes infected with both a drug-resistant virus and a wild-type virus are low. This implies that outgrowth of wild-type virus cannot occur. The only possibility, therefore, to become wild-type virus is through reversion. We would argue that whether or not reversion will take place depends on the RC effects of the intermediate variants.
If reversion of single mutations would lead to a decrease in RC, PI-resistant viruses with multiple protease mutations will persist. But when reversion leads to an increase in RC, these viruses may gradually revert to wild type. Further studies are needed to evaluate to what extent the RC of intermediate variants determines evolution in these situations.
The (partial) disappearance of mutations in protease has been observed in a few highly PI-experienced patients who were switched from a PI-containing regimen to a new regimen without PIs [20] . In this particular set of patients, the outgrowth of archived NRTI-resistant viruses may account for the observed disappearance of PI mutations, because both patients were also switched to another NRTI and/or nonnucleoside RTI regimen once the PI was removed from their regimen. Strikingly, in the few studies that have investigated the evolution of drug-resistant protease mutants in the absence of drug pressure (e.g., after transmission as well as after stopping PIs while continuing RTIs), a complete reversion to wild type has not been observed to date. Limited follow-up time may be the cause of this observation, but it can still be concluded that drug-resistant protease mutants can persist for a prolonged period of time.
The findings of our study are in agreement with those of a recent study in which patients interrupting their PI were also investigated [19] . Both studies demonstrate no apparent increase in viral load after interruption of the PI. These data suggest that, in the investigated patients, the PI no longer had a suppressive effect on viral replication. Taken together, these data show that, even after withdrawal of a PI, under certain conditions viruses with a reduced RC can persist. Clinical trials should further investigate whether this translates into a clinical effect. However, in our opinion this PTI would only have potential value in patients who have experienced multiple failures on PI-containing regimens and for whom no other therapeutic options are available.
In conclusion, despite a reduced RC, drug-resistant protease mutants may persist in vivo in absence of PIs. Persistence is independent of the actual RC value but is determined by the effects on RC of the intermediate variants. In the situation that changing of single amino acids to wild type leads to a (further) reduction in RC, reversion to wild type is blocked, and PIresistant viruses with multiple mutations in protease and a reduced RC may persist as a result of compensatory fixation. Further studies are warranted to determine in which situations these principles apply and whether they can be exploited clinically.
